NOT FOR DISTRIBUTION
Header cover image

Market Cap

CN¥29.5b

Last Updated

2021/04/11 09:09 UTC

Data Sources

Company Financials +

Executive Summary

Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. More Details


Snowflake Analysis

Solid track record with reasonable growth potential.

Share Price & News

How has Haisco Pharmaceutical Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 002653 is more volatile than 75% of CN stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: 002653's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.


Market Performance


7 Day Return

6.4%

2653

-0.1%

CN Pharmaceuticals

-1.1%

CN Market


1 Year Return

31.6%

2653

15.8%

CN Pharmaceuticals

28.4%

CN Market

Return vs Industry: 002653 exceeded the CN Pharmaceuticals industry which returned 15.8% over the past year.

Return vs Market: 002653 exceeded the CN Market which returned 28.4% over the past year.


Shareholder returns

2653IndustryMarket
7 Day6.4%-0.1%-1.1%
30 Day13.5%3.9%1.0%
90 Day59.6%-5.4%-5.8%
1 Year32.0%31.6%16.9%15.8%30.4%28.4%
3 Year133.7%123.9%25.2%20.7%25.9%19.9%
5 Year76.0%60.3%41.6%34.1%23.6%15.5%

Long-Term Price Volatility Vs. Market

How volatile is Haisco Pharmaceutical Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Haisco Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?

47.05x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 002653 (CN¥27.76) is trading above our estimate of fair value (CN¥4.74)

Significantly Below Fair Value: 002653 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 002653 is poor value based on its PE Ratio (47.1x) compared to the CN Pharmaceuticals industry average (31.2x).

PE vs Market: 002653 is poor value based on its PE Ratio (47.1x) compared to the CN market (33.9x).


Price to Earnings Growth Ratio

PEG Ratio: 002653 is poor value based on its PEG Ratio (2.1x)


Price to Book Ratio

PB vs Industry: 002653 is overvalued based on its PB Ratio (10.9x) compared to the CN Pharmaceuticals industry average (2.7x).


Future Growth

How is Haisco Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

22.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 002653's forecast earnings growth (22.5% per year) is above the savings rate (3.3%).

Earnings vs Market: 002653's earnings (22.5% per year) are forecast to grow slower than the CN market (23.4% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 002653's revenue (18.7% per year) is forecast to grow faster than the CN market (17.9% per year).

High Growth Revenue: 002653's revenue (18.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 002653's Return on Equity is forecast to be high in 3 years time (21%)


Past Performance

How has Haisco Pharmaceutical Group performed over the past 5 years?

9.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 002653 has a high level of non-cash earnings.

Growing Profit Margin: 002653's current net profit margins (19.1%) are higher than last year (12.6%).


Past Earnings Growth Analysis

Earnings Trend: 002653's earnings have grown by 9.3% per year over the past 5 years.

Accelerating Growth: 002653's earnings growth over the past year (28.7%) exceeds its 5-year average (9.3% per year).

Earnings vs Industry: 002653 earnings growth over the past year (28.7%) exceeded the Pharmaceuticals industry 10.8%.


Return on Equity

High ROE: 002653's Return on Equity (21.1%) is considered high.


Financial Health

How is Haisco Pharmaceutical Group's financial position?


Financial Position Analysis

Short Term Liabilities: 002653's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥1.7B).

Long Term Liabilities: 002653's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥425.6M).


Debt to Equity History and Analysis

Debt Level: 002653's debt to equity ratio (38.7%) is considered satisfactory.

Reducing Debt: 002653's debt to equity ratio has increased from 29.2% to 38.7% over the past 5 years.

Debt Coverage: 002653's debt is not well covered by operating cash flow (18.7%).

Interest Coverage: 002653 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Haisco Pharmaceutical Group current dividend yield, its reliability and sustainability?

1.34%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 002653's dividend (1.34%) is higher than the bottom 25% of dividend payers in the CN market (0.43%).

High Dividend: 002653's dividend (1.34%) is low compared to the top 25% of dividend payers in the CN market (1.81%).


Stability and Growth of Payments

Stable Dividend: 002653 has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: 002653's dividend payments have increased, but the company has only paid a dividend for 9 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (63.1%), 002653's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average board tenure


CEO

Jun Min Wang (50 yo)

no data

Tenure

CN¥319,300

Compensation

Mr. Wang Jun Min is the Founder of Haisco Pharmaceutical and also serves as its President and Chief Executive Officer. Mr. Wang serves as the Chairman and General Manager of Haisco Pharmaceutical Group Co....


Board Members

Experienced Board: 002653's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Haisco Pharmaceutical Group Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Haisco Pharmaceutical Group Co., Ltd.
  • Ticker: 2653
  • Exchange: SZSE
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥29.532b
  • Shares outstanding: 1.06b
  • Website: https://www.haisco.com

Number of Employees


Location

  • Haisco Pharmaceutical Group Co., Ltd.
  • Taiwan Strait Technology Industry Development Park
  • No. 136, Baili Road
  • Chengdu
  • Sichuan Province
  • China

Listings


Biography

Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. The company offers capsules, tablets, granules, and bulk drugs in the fields of cardiova...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 09:09
End of Day Share Price2021/04/09 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.